GH:NSD-Guardant Health Inc (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 40.62

Change

+2.07 (+5.37)%

Market Cap

USD 5.04B

Volume

2.50M

Analyst Target

USD 110.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 37.95B
NTRA Natera Inc

N/A

USD 20.66B
ILMN Illumina Inc

N/A

USD 11.99B
ICLR ICON PLC

N/A

USD 11.79B
EXAS EXACT Sciences Corporation

N/A

USD 10.87B
MEDP Medpace Holdings Inc

N/A

USD 8.65B
RDNT RadNet Inc

N/A

USD 4.31B
SHC Sotera Health Co

N/A

USD 3.45B
VCYT Veracyte Inc

N/A

USD 2.51B
WGS GeneDx Holdings Corp.

N/A

USD 1.95B

ETFs Containing GH

ARCG:LSE ARK Genomic Revolution UC.. 4.71 % 0.00 %

N/A

USD 8.76M
ARKG:LSE ARK Genomic Revolution UC.. 4.71 % 0.00 %

N/A

USD 8.76M
DOCG:LSE L&G Healthcare Breakthrou.. 2.59 % 0.00 %

N/A

USD 0.06B
DOCT:LSE L&G Healthcare Breakthrou.. 2.59 % 0.00 %

N/A

USD 0.06B
DOCT:SW L&G Healthcare Breakthrou.. 2.47 % 0.00 %

N/A

USD 0.06B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

N/A

USD 0.89B
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.96% 89% A- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.96% 89% A- 90% A-
Trailing 12 Months  
Capital Gain 49.89% 86% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 49.89% 86% B+ 88% B+
Trailing 5 Years  
Capital Gain -55.06% 48% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -55.06% 44% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -14.28% 37% F 20% F
Dividend Return -14.28% 37% F 20% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 52.90% 56% F 34% F
Risk Adjusted Return -27.00% 37% F 24% F
Market Capitalization 5.04B 84% B 89% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector